MedTrace Logo

Creatine as a New Therapeutic Strategy in Depression

NCT00313417 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-04-05

No results posted yet for this study

Summary

Creatine as a new therapeutic strategy in depression:

A double-blind, parallel, randomized, add-on clinical trial of creatine versus placebo added to antidepressant treatment of patients with major depressive episode.

Conditions

Interventions

DIETARY_SUPPLEMENT

Creatine monohydrate

Up to 10 grams

OTHER

Placebo

Placebo will be given in the same way and appearance as the active treatment

Sponsors & Collaborators

  • Beersheva Mental Health Center

    collaborator OTHER_GOV

  • Herzog Hospital

    lead OTHER

Principal Investigators

  • Joseph Levine, Prof. · Beer Sheva Mental Health Center Israel.

  • Boris Nemets, Dr. · Beer Sheva Mental Health Center Israel.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313417 on ClinicalTrials.gov